A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.
